TRANS-FOODS: Preventing Peanut Allergy Through Improved Understanding of the Transcutaneous Sensitisation Route, Novel Food Processing and Skin Care Adaptations
NCT ID: NCT05407012
Last Updated: 2024-05-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
120 participants
INTERVENTIONAL
2024-04-05
2025-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. Establish if peanut allergen components can pass into human skin through regular massage using the peanut protein-containing extract.
2. Clarify whether this effect is amplified in those with an impaired skin barrier (AD and dry skin vs healthy controls).
3. Assess whether peanut protein components can be detected in interstitial skin fluid (ISF) using a suction device.
4. Test whether peanut protein components present in ISF are able to induce activation of basophils in blood of peanut allergic donors.
5. Assess whether the transcutaneous uptake of peanut protein can be reduced by the prior use of a barrier enhancing cream.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Early Peanut Introduction: Translation to Clinical Practice
NCT03019328
Study of Tolerance to Oral Peanut
NCT01259804
The Effect of Extrinsic Factors on Food Allergy
NCT01429896
Study to Assess Tolerance of Traces in Peanut/Tree Nut Allergic Children.
NCT03680066
Peanut Oral Induction Tolerance in Peanut's Allergic Teenagers
NCT02046083
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Cutaneous exposure of allergens is a crucial, but hitherto under explored route of food sensitisation, that if understood could lead to the development of translatable strategies to prevent food allergy. Food processors require a greater understanding of how allergen exposure cause allergy so that they can adapt their processing methods to counteract these exposure processes. Furthermore, this proposed research aligns with on-going efforts across Europe to address the increasing problems associated with food allergy but it is unique in that it focuses on cutaneous allergen exposure, which is a field in desperate need of more systematic study.
The assembled team of investigators (from the UK, Germany and France) joined by a peanut industry partner (Levantine) and patient and consumer representatives will aim to address the following hypotheses:
Understanding the mechanisms by which:
* Peanut proteins pass into the skin via the appendages to trigger an immune response.
* Skin stretching that occurs during massage opens up the skin appendages allowing more peanut protein into the skin and leads to dendritic cell activation and induction of T helper 2 cell response.
* Co-administration of peanut proteins and an oil to the skin increases allergenicity.
* Skin barrier impairment and inflammation (AD) increases allergenicity.
Test novel approaches to peanut allergy prevention whereby:
* Modifications in peanut processing can reduce allergen exposure via the skin.
* Meticulous hand hygiene reduces skin contamination with peanut protein.
* Application of a barrier enhancing cream can strengthen the skin barrier, in particular in those with atopic dermatitis, and reduce the risk of transcutaneous sensitisation further.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intervention of the barrier enhancing preparation
Dry skin or atopic dermatitis or healthy skin; application of the peanut protein extract +/- massage after extract application.
Application of the barrier enhancing preparation.
Application of the barrier enhancing preparation around 30 minutes before application of the peanut protein extract +/- massage after extract application;
Absence of the barrier enhancing preparation
Dry skin or atopic dermatitis or healthy skin; application of the peanut protein extract +/- massage after extract application.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Application of the barrier enhancing preparation.
Application of the barrier enhancing preparation around 30 minutes before application of the peanut protein extract +/- massage after extract application;
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Willingness to apply the study intervention and to not use any other topical preparations over theforearms during the study period.
Exclusion Criteria
* Positive skin prick test to peanut (\>0 mm).
* No regular consumption of peanut products.
* Widespread AD, in particular if this involves the test sites of the forearms.
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Bonn
OTHER
Institut Curie
OTHER
Charite University, Berlin, Germany
OTHER
Levantine UK
UNKNOWN
King's College London
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Carsten Flohr
Role: PRINCIPAL_INVESTIGATOR
King's College London
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Unit for Population-Based Dermatology Research
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RE19787
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.